Sun Pharmaceutical Industries Resultados de beneficios anteriores
Pasado controles de criterios 5/6
Sun Pharmaceutical Industries ha aumentado sus beneficios a una tasa media anual de 28.5%, mientras que los beneficios de la industria de Pharmaceuticals han experimentado un crecimiento de 13.3% anual. Los ingresos han ido creciendo a una tasa media de 10.4% al año. La rentabilidad financiera de Sun Pharmaceutical Industries es de 16%, y sus márgenes netos son de 22%.
Información clave
28.5%
Tasa de crecimiento de los beneficios
28.6%
Tasa de crecimiento del BPA
| Crecimiento de la industria Pharmaceuticals | 17.5% |
| Tasa de crecimiento de los ingresos | 10.4% |
| Rentabilidad financiera | 16.0% |
| Margen neto | 22.0% |
| Última actualización de beneficios | 30 Sep 2024 |
Actualizaciones de resultados anteriores recientes
Recent updates
Does Sun Pharmaceutical Industries (NSE:SUNPHARMA) Have A Healthy Balance Sheet?
Nov 18
Sun Pharmaceutical Industries Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Oct 31We Ran A Stock Scan For Earnings Growth And Sun Pharmaceutical Industries (NSE:SUNPHARMA) Passed With Ease
Oct 21Pinning Down Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) P/E Is Difficult Right Now
Aug 24Sun Pharmaceutical Industries Limited Just Beat EPS By 10%: Here's What Analysts Think Will Happen Next
Aug 06This Is The Reason Why We Think Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) CEO Might Be Underpaid
Jul 30Sun Pharmaceutical Industries (NSE:SUNPHARMA) Ticks All The Boxes When It Comes To Earnings Growth
Jun 30Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet
Jun 12Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year
May 25Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) Price Is Out Of Tune With Earnings
May 22Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet
Mar 13Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's
Feb 03Here's Why We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Might Deserve Your Attention Today
Jan 05Getting In Cheap On Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Is Unlikely
Dec 18Is Now The Time To Put Sun Pharmaceutical Industries (NSE:SUNPHARMA) On Your Watchlist?
Oct 04Should You Be Adding Sun Pharmaceutical Industries (NSE:SUNPHARMA) To Your Watchlist Today?
Jul 03We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Can Manage Its Debt With Ease
Jun 15Is Sun Pharmaceutical Industries (NSE:SUNPHARMA) A Risky Investment?
Mar 14Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Increasing Its Dividend To ₹7.50
Feb 03These 4 Measures Indicate That Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Using Debt Reasonably Well
Dec 09Does This Valuation Of Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Imply Investors Are Overpaying?
Oct 13These 4 Measures Indicate That Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Using Debt Safely
Sep 04Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's
Aug 05Desglose de ingresos y gastos
Cómo gana y gasta dinero Sun Pharmaceutical Industries. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 30 Sep 24 | 503,077 | 110,541 | 96,684 | 0 |
| 30 Jun 24 | 492,088 | 103,895 | 95,551 | 0 |
| 31 Mar 24 | 484,969 | 95,764 | 95,025 | 0 |
| 31 Dec 23 | 474,446 | 89,063 | 93,681 | 0 |
| 30 Sep 23 | 463,049 | 85,485 | 90,419 | 0 |
| 30 Jun 23 | 450,648 | 84,352 | 86,821 | 0 |
| 31 Mar 23 | 438,857 | 84,736 | 83,549 | 0 |
| 31 Dec 22 | 424,018 | 42,119 | 80,549 | 0 |
| 30 Sep 22 | 410,239 | 41,047 | 78,688 | 0 |
| 30 Jun 22 | 396,975 | 38,894 | 76,169 | 0 |
| 31 Mar 22 | 386,545 | 32,727 | 73,544 | 0 |
| 31 Dec 21 | 377,307 | 64,441 | 71,354 | 0 |
| 30 Sep 21 | 367,044 | 62,378 | 70,049 | 0 |
| 30 Jun 21 | 356,316 | 60,036 | 68,619 | 0 |
| 31 Mar 21 | 334,981 | 29,038 | 69,042 | 0 |
| 31 Dec 20 | 331,601 | 24,095 | 68,729 | 0 |
| 30 Sep 20 | 324,782 | 14,706 | 67,016 | 0 |
| 30 Jun 20 | 320,484 | 7,219 | 65,810 | 0 |
| 31 Mar 20 | 328,375 | 37,649 | 63,986 | 0 |
| 31 Dec 19 | 318,165 | 40,010 | 64,149 | 0 |
| 30 Sep 19 | 314,018 | 43,293 | 63,608 | 0 |
| 30 Jun 19 | 302,161 | 29,956 | 62,101 | 0 |
| 31 Mar 19 | 290,659 | 26,654 | 61,027 | 0 |
| 31 Dec 18 | 288,052 | 34,379 | 58,539 | 0 |
| 30 Sep 18 | 277,182 | 24,380 | 57,316 | 0 |
| 30 Jun 18 | 275,048 | 35,690 | 54,702 | 0 |
| 31 Mar 18 | 264,155 | 20,957 | 54,814 | 0 |
| 31 Dec 17 | 263,811 | 20,763 | 54,007 | 0 |
| 30 Sep 17 | 276,530 | 31,827 | 52,432 | 0 |
| 30 Jun 17 | 295,310 | 45,057 | 49,929 | 0 |
| 31 Mar 17 | 313,081 | 69,644 | 50,285 | 0 |
| 31 Dec 16 | 319,185 | 73,270 | 49,986 | 0 |
| 30 Sep 16 | 311,431 | 74,000 | 49,212 | 0 |
| 30 Jun 16 | 297,512 | 61,937 | 48,012 | 0 |
| 31 Mar 16 | 281,086 | 45,457 | 49,076 | 0 |
| 31 Dec 15 | 266,281 | 38,915 | 95,369 | 0 |
| 30 Sep 15 | 264,670 | 28,702 | 95,000 | 0 |
| 30 Jun 15 | 276,422 | 38,150 | 45,608 | 0 |
| 31 Mar 15 | 273,920 | 45,394 | 46,483 | 0 |
| 31 Dec 14 | 170,765 | 59,141 | 45,586 | 0 |
| 30 Sep 14 | 170,835 | 60,202 | 45,036 | 0 |
| 30 Jun 14 | 165,250 | 58,100 | 44,680 | 0 |
| 31 Mar 14 | 160,804 | 31,415 | 44,040 | 0 |
| 31 Dec 13 | 150,933 | 26,104 | 35,071 | 0 |
Ingresos de calidad: SUNPHARMA tiene ganancias de alta calidad.
Margen de beneficios creciente: Los actuales márgenes de beneficio (22%) de SUNPHARMA son superiores a los del año pasado (18.5%).
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: En los últimos 5 años, los beneficios de lSUNPHARMA han crecido significativamente en un 28.5% al año.
Acelerando crecimiento: El crecimiento de los beneficios de SUNPHARMA en el último año (29.3%) supera su media de 5 años (28.5% al año).
Beneficios vs. Industria: El crecimiento de los beneficios de SUNPHARMA en el último año (29.3%) superó al de la industria Pharmaceuticals 20.5%.
Rentabilidad financiera
Alta ROE: La rentabilidad financiera de SUNPHARMA (16%) se considera baja.